Chugai Pharmaceutical Co., Ltd. (TYO:4519)

Market Cap	11.39T
Revenue (ttm)	1.17T
Net Income (ttm)	387.32B
Shares Out	1.65B
EPS (ttm)	235.36
PE Ratio	29.41
Forward PE	26.65
Dividend	100.00 (1.45%)
Ex-Dividend Date	Dec 27, 2024

Volume	1,494,600
Average Volume	2,466,215
Open	7,048.00
Previous Close	6,921.00
Day's Range	6,957.00 - 7,085.00
52-Week Range	4,572.00 - 7,979.00
Beta	0.54
RSI	50.26
Earnings Date	Apr 24, 2025

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrys...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,604
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4519

Financial Performance

In 2024, Chugai Pharmaceutical's revenue was 1.17 trillion, an increase of 5.33% compared to the previous year's 1.11 trillion. Earnings were 387.32 billion, an increase of 19.00%.